Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  
                                 
 

Journal of Clinical Trials


Open Access
 
 
 
ISSN: 2167-0870
 
 
 
home » journals » base-of-a-research-good-clinical-practice-in-clinical-trials-2167-0870 Rss Feed Rss Feed
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals that operates with the help of 50,000 + Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and
Workshops on Pharma, Medicine, Science and Technology
 
 
Review Article Open Access
 
Base of a Research: Good Clinical Practice in Clinical Trials
Kapil Verma*
Amity Institute of Forensic Sciences (AIFS), Amity University, Uttar Pradesh, India
Corresponding Author : Kapil Verma
Amity Institute of Forensic Sciences (AIFS)
B-Block, Lower ground floor, Amity University
Uttar Pradesh Sec-125, Noida-201303, Uttar Pradesh, India
E-mail: forensic.kapilalert@gmail.com
 
Received December 21, 2012; Accepted January 24, 2013; Published January 27, 2013
 
Citation: Verma K (2013) Base of a Research: Good Clinical Practice in Clinical Trials. J Clin Trials 3:128. doi: 10.4172/2167-0870.1000128
 
Copyright: © 2013 Verma K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
 
Related article at
DownloadPubmed DownloadScholar Google
 
Visit for more related articles at
DownloadJournal of Clinical Trials
 
Abstract
 

This article illustrates the importance of Good Clinical Practice (GCP), defines and outlines the goals of GCP, presents a historical perspective on GCP and Outlines FDA regulations relating to GCP. Ongoing research shows that whether conducting research involving a new drug, a behavioral intervention, or an interview/survey, Good Clinical Practice (GCP) provides investigators and their study teams with the tools to protect human subjects and collect quality data. In this article, the author will define GCP, explain the benefits of following GCP for all types of human research and clinical trial studies, and provide some resources to assist investigators in implementing the tenets of GCP for their own research studies. This article reviews the impact of Good Clinical Practice (GCP) on clinical trials. GCP is likely to follow the International Conference on Harmonization of GCP guidelines in many aspects. GCP will enforce tighter guidelines on ethical aspects of a clinical study. Higher standards will be required in terms of comprehensive documentation for the clinical protocol, record keeping, training, and facilities including computers. Quality assurance and inspections will ensure that these standards are achieved. The additional requirements of GCP are discussed and any advantage to the study subject. GCP aims to ensure that the studies are scientifically authentic and that the clinical properties of the investigational product are properly documented. In this paper, we address the background history and the events that led up to the formation of these guidelines. Today, the GCP are used in clinical trials throughout the globe with the main aim of protecting and preserving human rights.

 
Keywords
 
Good Clinical Practice (GCP); ICH-GCP; Quality assurance; Inspections; Clinical trial; Human rights protection
 
Introduction
 
GCP is a key requirement for anyone involved in the conduct of clinical research is Good Clinical Practice (GCP) training. GCP is the standard and guidelines to which all research is conducted. GCP is a set of internationally-recognized ethical and scientific quality requirements that must be observed throughout the various stages of a clinical trial. Clinical trial following testing in laboratories and animal studies, the most promising treatments is moved into clinical trials [1]. A clinical trial is sometimes called a clinical study [2]. A clinical trial:
 
• Is a research study that tests how well an intervention works in a group of people
 
• Tests for new methods of screening, prevention, diagnosis, or therapy
 
• Is conducted in phases
 
During a trial, additional information is learned about an intervention, its risks, and its effectiveness and/or efficacy. Trials can only be conducted if there is an uncertainty about the outcome-trials cannot be conducted if the outcome is already known from a previous study [3,4]. Good Clinical Practice (GCP) is one of the basic sets of rules for hospitals, researchers and pharmaceutical companies engaged in clinical [5].
 
GCP or Good Clinical Practice refers to an international quality standard provided by the ICH for the purpose of regulating clinical trials that involve human subjects. GCP standards offer assurance as to the effect and safety of compounds developed in clinical trials, human rights protection of trial participants, and also define the roles of clinical research investigators, clinical trial sponsors and clinical research associates.
 
The fundamental tenet of GCP is that in research on man, the interest of science and society should never take precedence over considerations related to the well being of the study subject [5]. It aims to ensure that the studies are scientifically and ethically sound and that the clinical properties of the pharmaceutical substances under investigation are properly documented. The guidelines seek to establish two cardinal principles: protection of the rights of human subjects and authenticity of biomedical data generated. It ensures that the studies are implemented and reported in such a manner that there is public assurance that the data are credible, accurate and that the rights, integrity and confidentiality of the subjects are protected.
 
ICH-GCP
 
The objective of this ICH GCP Guideline [6] is to provide a unified standard for the European Union (EU), Japan and the United States to facilitate the mutual acceptance of clinical data by the regulatory authorities in these jurisdictions. The International conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH) [7,8] is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration. The guideline was developed with consideration of the current good clinical practices of the European Union, Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organization (WHO). This guideline should be followed when generating clinical trial data that are intended to be submitted to regulatory authorities. The principles established in this guideline may also be applied to other clinical investigations that may have an impact on the safety and well-being of human subjects [9]. The objective of such harmonization is a more economical use of human, animal and material resources, and the elimination of unnecessary delay in the global development and availability of new medicines whilst maintaining safeguards on quality, safety and efficacy, and regulatory obligations to protect public health [10-12].
 
Clinical studies should be carried out according to International Conference on Harmonisation (ICH)/WHO Good Clinical Practice standards [13]. This provides a unified standard for the European Union (EU) [14,15], Japan, and the United States, as well as those of Australia, Canada, the Nordic countries and the World Health Organisation (WHO). Thus, any country that adopts this guideline technically follows this same standard. The purpose is to make recommendations on ways to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for product registration in order to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines.
 
Principles of GCP
 
1. The rights, safety and well-being of the trial subjects shall prevail over the interests of science and society.
 
2. Each individual involved in conducting a trial shall be qualified by education, training and experience to perform his tasks.
 
3. Clinical trials shall be scientifically sound and guided by ethical principles in all their aspects.
 
4. The necessary procedures to secure the quality of every aspect of the trial shall be complied with.
 
5. The available non-clinical and clinical information on an investigational medicinal product shall be adequate to support the proposed clinical trial.
 
6. Clinical trials shall be conducted in accordance with the principles of the Declaration of Helsinki.
 
7. The protocol shall provide for the definition of inclusion and exclusion of subjects participating in a clinical trial, monitoring and publication policy.
 
8. The investigator and sponsor shall consider all relevant guidance with respect to commencing and conducting a clinical trial.
 
9. All clinical information shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified, while the confidentiality of records of the trial subjects remains protected.
 
10. Before the trial is initiated, foreseeable risks and inconveniences have been weighed against the anticipated benefit for the individual trial subject and other present and future patients. A trial should be initiated and continued only if the anticipated benefits justify the risks.
 
11. The medical care given to, and medical decisions made on behalf of, subjects shall always be the responsibility of an appropriately qualified doctor or, when appropriate, of a qualified dentist.
 
12. A trial shall be initiated only if an ethics committee and the licensing authority comes to the conclusion that the anticipated therapeutic and public health benefits justify the risks and may be continued only if compliance with this requirement is permanently monitored.
 
13. The rights of each subject to physical and mental integrity, to privacy and to the protection of the data concerning him in accordance with the Data Protection Act 1998 are safeguarded.
 
14. Provision has been made for insurance or indemnity to cover the liability of the investigator and sponsor which may arise in relation to the clinical trial.
 
Overview of the Clinical Research Process
 
Key trial activities include
 
• Development of the trial protocol
 
• Development of Standard Operating Procedures (SOPs)
 
• Development of support systems and tools
 
• Generation and approval of trial-related documents
 
• Selection of trial sites and the selection of properly qualified, trained, and experienced investigators and study personnel
 
• Ethics committee review and approval of the protocol
 
• Review by regulatory authorities
 
• Enrollment of subjects into the study: recruitment, eligibility, and informed consent
 
• The investigational product(s): quality, handling and accounting
 
• Trial data acquisition: conducting the trial
 
• Safety management and reporting
 
• Monitoring the trial
 
• Managing trial data [16-18]
 
• Quality assurance of the trial performance and data
 
• Reporting the trial
 
Common GCP Issue During Clinical Studies
 
Informed consent
 
Correct version
 
• Length of consent form
 
• Copy to patients
 
• Documentation - of contacts, in source files etc.
 
• Translations
 
• Ethics committee approval and information to ongoing patients
 
• Witness
 
Recruitment and study procedures
 
Screening procedures before consent
 
• Incomplete laboratory workup per protocol
 
• Inclusion/Exclusion exceptions not discussed with medical monitor
 
• Patient visits outside the protocol allowed window
 
• Advertisements not approved by sponsor/ethics committees
 
• Difficulties in enrollment - action from investigator and sponsor
 
Monitoring
 
Source data problems
 
• CRF completion quality
 
• Study team training issues
 
• Incomplete essential documentation
 
• Monitoring frequency issues
 
Clinical trial supplies
 
Randomization errors
 
• Accountability problems
 
• Improper storage conditions
 
• Compliance issues
 
• Blind breaking issues
 
Safety reporting
 
Unreported SAEs
 
• Delayed reporting of SAEs
 
• Documentation in source files of AEs and SAEs
 
• SAE reporting to institutional ethics committee
 
• Additional safety information to ongoing/new patients- consent addenda/amendments.
 
• Updates to investigators’ brochure (Tables 1-4)
 
Conclusion
 
Ongoing research shows that whether conducting research involving a new drug, a behavioral intervention, or an interview/survey, Good Clinical Practice (GCP) [19-24] provides investigators and their study teams with the tools to protect human subjects and collect quality data. In this article, the author will define GCP, explain the benefits of following GCP for all types of human research studies, and provide some resources to assist investigators in implementing the tenets of GCP for their own research studies. This article illustrates the importance of Good Clinical Practice (GCP), defined and outlined the goals of GCP, Presented a historical perspective on GCP, Outlined FDA regulations relating to GCP.
 
According to Van Dongen [4] ultimately it is not difficult for investigators and their study teams to follow GCP – it is simply a question of writing down procedures, documenting what is being done, and preparing for inspection. He goes on to say that there are considerable rewards, not the least of which is the confidence that the data was obtained through a GCP-compliant research study. GCP will enforce tighter guidelines on ethical aspects of a clinical study. Higher standards will be required in terms of comprehensive documentation for the clinical protocol, record keeping, training, and facilities including computers. The additional requirements of GCP are discussed and any advantage to the study subject. GCP aims to ensure that the studies are scientifically authentic and that the clinical properties of the investigational product are properly documented. In this paper, we address the background history and the events that led up to the formation of these guidelines. Today, the GCP are used in clinical trials throughout the globe with the main aim of protecting and preserving human rights. Quality assurance and inspections will ensure that these standards are achieved. This article reviews the impact of Good Clinical Practice (GCP) on clinical trials.
 
References
 
























 
References

























Tables at a glance

     
Table 1  Table 2  Table 3  Table 4
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
About Journal
Journal Home
Editorial Board Members
Current Issue
Previous Issue
Archive
Instructions for Authors
Submit Manuscript
Contact Editorial Office
 
Related Journals
Epidemiology: Open Access
Journal of Clinical Research & Bioethics
 
Related Conferences
4th International Conference and Exhibition on Pharmacovigilance & Clinical Trials
August 10-12, 2015 London, UK
International Conference on Clinical Trials
July 27-29, 2015 Florida, USA
 
Article Tools
Export citation
Share/Blog this article
Recommend to your Librarian
 
Article usage
  Total views: 10896
  [From(publication date):
February-2013 - Aug 04, 2015]
  Breakdown by view type
  HTML page views : 7077
  PDF downloads :3819
 
Subject wise
Open Access Journals
Clinical Journals
Chemistry Journals
Engineering Journals
Environmental Journals
Life Sciences Journals
  Read More »

Post your comment

Name:
E-mail:
Your question:
Anti Spam Code:
  Reload  Can't read the image? click here to refresh

OMICS International Conferences 2015-16

Meet Inspiring Speakers and Experts at our 1000+ Global Annual Meetings
Conferences By Country
  USA   Spain   Poland
  Australia   Canada   Austria
  UAE   Switzerland   Turkey
  Italy   France   Finland
  Germany   India   Ukraine
  UK   Malaysia   Denmark
  Japan   Singapore   Mexico
  Brazil   South Africa   Norway
  South Korea   New Zealand   China
  Netherlands   Philippines
 
Medical & Clinical Conferences
Microbiology Oncology & Cancer
Diabetes & Endocrinology Cardiology
Nursing Dentistry
Healthcare Management Physical Therapy Rehabilitation
Neuroscience Psychiatry
Immunology Infectious Diseases
Gastroenterology Medical Ethics & Health Policies
Genetics & Molecular Biology Palliativecare
Pathology Reproductive Medicine & Women Healthcare
Alternative Healthcare Surgery
Pediatrics Radiology
Ophthalmology  
 
Conferences by Subject
Pharmaceutical Sciences
Pharma Marketing & Industry
Nutrition
Environmental Science
Physics & Materials Science
Environmental
EEE & Engineering
Veterinary
Chemical Engineering
Business Management
Massmedia
Geology & Earth science
 
 
20082014 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version